Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) shares, rose in value on Wednesday, 06/22/22, with the stock price up by 12.07% to the previous day’s close as strong demand from buyers drove the stock to $1.95.
Actively observing the price movement in the last trading, the stock closed the session at $1.74, falling within a range of $1.715 and $2.0889. The value of beta (5-year monthly) was 1.53. Referring to stock’s 52-week performance, its high was $6.33, and the low was $1.31. On the whole, LXRX has fluctuated by 10.17% over the past month.
With the market capitalization of Lexicon Pharmaceuticals Inc. currently standing at about $275.67 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 08, 2022 – Mar 14, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.15, which is expected to increase to -$0.14 for fiscal year -$0.62 and then to about -$0.54 by fiscal year 2023. Data indicates that the EPS growth is expected to be -3.30% in 2023, while the next year’s EPS growth is forecast to be 12.90%.
Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $170k, representing a decrease of -43.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that LXRX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of LXRX currently trading nearly 19.38% and 6.50% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.11, while the 7-day volatility ratio is showing 12.85% which for the 30-day chart, stands at 8.68%. Furthermore, Lexicon Pharmaceuticals Inc. (LXRX)’s beta value is 1.57, and its average true range (ATR) is 0.15. The company’s stock has been forecasted to trade at an average price of $11.50 over the course of the next 52 weeks, with a low of $5.00 and a high of $18.00. Based on these price targets, the low is -156.41% off current price, whereas the price has to move -823.08% to reach the yearly target high. Additionally, analysts’ median price of $11.50 is likely to be welcomed by investors because it represents a decrease of -489.74% from the current levels.
A comparison of Lexicon Pharmaceuticals Inc. (LXRX) with its peers suggests the former has fared considerably weaker in the market. LXRX showed an intraday change of 12.07% in last session, and over the past year, it shrunk by -58.33%%. In comparison, Aerie Pharmaceuticals Inc. (AERI) has moved lower at -0.88% on the day and was down -61.72% over the past 12 months. On the other hand, the price of Thermo Fisher Scientific Inc. (TMO) has risen 1.11% on the day. The stock, however, is off 5.49% from where it was a year ago. Additionally, there is a gain of 0.10% for Ligand Pharmaceuticals Incorporated (LGND) in last trading while the stock has seen an overall depriciation of -37.91%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.15%.
Data on historical trading for Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) indicates that the trading volumes over the past 3 months, they’ve averaged 499.34K. According to company’s latest data on outstanding shares, there are 149.15 million shares outstanding.
Nearly 1.30% of Lexicon Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 83.80% of the company’s shares. The stock has fallen by -50.51% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LXRX stock heading into the next quarter.